19 septrushano 22 (Georgensel) outerusham accorbason accument reparationum 10240 19 Sel Bardénanhaung 22 (Bitanutroh), Bardénanhaung Rd., Huamark Sanglagit Banglack 1024 464 mr 2 Stá 5000 Tea 10 0007545000440



No. HEMP-005/2022

February 3, 2022

Subject: Notification of the record date to determine the list of shareholders entitled to be allocated with

the warrants to purchase newly issued ordinary shares of Health Empire Corporation Public Company

Limited Series 2 (HEMP-W2) (Record Date)

To: President

The Stock Exchange of Thailand

Whereas the Extraordinary General Meeting of Shareholders No. 2/2021 of Health Empire Corporation Public Company (the "Company"), held on November 26, 2021, approved the issuance of the warrants to purchase newly issued ordinary shares of the Company Series 2 (HEMP-W2) (the "HEMP-W2 Warrants") in the amount not exceeding 177,849,750 units for allocation to the Company's existing shareholders in proportion to their shareholding percentage (Right Offering) and the allocation of not exceeding 177,849,750 newly issued ordinary shares with a par value of THB 1.00 per share (number of HEMP-W2 Warrants and the newly issued ordinary shares are calculated on number of shares after the change of the par value of the Company's shares by way of reverse stock split from par value THB 1.00 per share to be THB 12.90 per share and the reduction of capital to write off accumulated losses by change of par value from THB 12.90 per share to be THB 1.00 per share) to accommodate the exercise of the HEMP-W2 Warrants for allocation to the Company's existing shareholders in proportion to their shareholding percentage, at the ratio of 2 existing ordinary shares to 1 unit of the HEMP-W2 Warrants, at the offering price of the HEMP-W2 Warrants at THB -0.00- per unit, including authorizing the Board of Directors or the Executive Committee or the Chief Executive Officer or any other person appointed and assigned by the Board of Directors or the Executive Committee or the Chief Executive Officer to have the power to determine the record date to determine the list of shareholders entitled to be allocated with the HEMP-W2 Warrants

In this regard, on February 3, 2022, the Board of Directors that is authorized by the Extraordinary General Meeting of Shareholders No. 2/2021 has determined the record date to determine the list of shareholders entitled to be allocated with the HEMP-W2 Warrants (Record Date) is February 21, 2022.

Other details of the HEMP-W2 Warrants will be set out in the Notification of the Allocation of the HEMP-W2 Warrants and the Terms and Conditions of the HEMP-W2 Warrants which the Company will prepare and deliver to the shareholders. The Company will submit a report of result of the allocation of the HEMP-W2 Warrants to the Stock of Exchange of Thailand ("SET") once the HEMP-W2 Warrants have been issued.

Remark: The issuance and offering of the HEMP-W2 Warrants shall be occurred after the issuance and offering of 1,655,262,500 newly issued ordinary shares by way of private placement and the completion of the registration of change of par value and the capital decrease in order to compensate share discount and the Company's accumulated losses with the Ministry of Commerce. Prior to the registration of capital decrease, the Company must send the advance notice to inform creditors about the capital decrease for a period of two months as required by applicable law and such two-month period from the notification date to the Company's creditors will be due on February 9, 2022. Afterward, the Company shall register the capital decrease in order to compensate share discount and the Company's accumulated losses. In order to protect the interests of all shareholders and investors, the Company therefore deems it appropriate to extend the issuance date of HEMP-W2 warrant from February 18, 2022 as proposed to Extraordinary General Meeting of Shareholders No. 2/2021 to February 28, 2022.

Please be informed accordingly

Sincerely yours,

- GEN. Surapan Poomkaew -

(GEN. Surapan Poomkaew)

The Chairman of the Board and Independent Director